ArticleUrology case reports2026
High-grade undifferentiated prostatic sarcoma with heterologous differentiation: A rare case report and literature review.
Article in Urology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary prostatic sarcomas are extremely rare, accounting for less than 0.1 % of prostatic malignancies. They arise from mesenchymal stromal cells and exhibit aggressive behavior. We report a 45-year-old man with progressive lower urinary tract symptoms, abdominal distension, and weight loss. Imaging revealed a large pelvic mass inseparable from the prostate. Exploratory laparotomy showed a >30 cm encapsulated tumor, completely excised with partial prostate. Histopathology confirmed a high-grade undifferentiated sarcoma with heterologous differentiation. At two-year follow-up, the patient remained disease-free. Complete surgical excision remains the cornerstone of management, while multimodal therapy may be considered for high-risk or recurrent cases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.